Computational and practical aspects of drug repositioning

Assay and Drug Development Technologies

Volumn 13, Issue 6, 2015, Pages 299-306

  Oprea, Tudor I ^a   Overington, John P ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIAMEBIC AGENT; ANTIMALARIAL AGENT;

AMEBIASIS; ARTICLE; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DATABASE; DRUG DEVELOPMENT; DRUG DOSE; DRUG EXPOSURE; DRUG INDICATION; DRUG REPOSITIONING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG USE; EVIDENCE BASED PRACTICE; HUMAN; HYPOTHESIS; MALARIA; NEGLECTED DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRACTICE GUIDELINE; ANIMAL; BIOLOGY; DRUG THERAPY; DYSENTERY, AMEBIC; PRECLINICAL STUDY; STATISTICS AND NUMERICAL DATA; TRENDS;

ANIMALS; ANTIMALARIALS; COMPUTATIONAL BIOLOGY; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; DRUG REPOSITIONING; DRUG THERAPY; DYSENTERY, AMEBIC; HUMANS;

EID: 84938697897     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2015.29011.tiodrrr     Document Type: Article

References (23)

1. Cavalla D. Predictive methods in drug repositioning: gold mine or just a bigger haystack. Drug Discov Today. 2013;18:523-532.
2. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310:1062-1075.
3. Furr BJA, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther. 1984;25:127-205.
4. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol. 1986;30:679-684.
5. Williams AJ, Ekins S. A quality alert and call for improved curation of public chemistry databases. Drug Discov Today. 2011;16:747-750.
6. Oprea TI, Olah M, Ostopovici L, Rad R, Mracec M. On the propagation of errors in the QSAR literature. In: Ford M, Livingstone D, Dearden J, Van de Waterbeemd H, eds. EuroQSAR 2002-Designing Drugs and Crop Protectants: Processes, Problems and Solutions. New York: Blackwell Publishing; 2003:314-315.
7. Jansman FGA, Reyners AKL, van Roon EN, et al. Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther. 2011;33:305-314.
8. Handley DA, Cervoni P, McCray JE, McCullough JR. Preclinical enantioselective pharmacology of (R)- and (S)- ketorolac. J Clin Pharmacol. 1998;38:25S-35S.
9. Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Therap Strategies. 2011;8:61-69.
10. ClinicalTrials.gov. Availability and effect of post-OP ketorolac on ovarian, fallopian tube or primary peritoneal cancer. http://clinicaltrials.gov/ct2/show/NCT01670799 (Last accessed November 22, 2014).
11. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006;2:415-416.
12. Medicines for Malaria Venture. Interactive R and D portfolio. www.mmv.org/research-development/rd-portfolio (Last accessed November 22, 2014).
13. Yuan J, Cheng KC-C, Johnson RL, et al. Chemical genomic profiling for antimalarial therapies, response signatures and molecular targets. Science. 2011;333:724-729.
14. Huang R, Southall N, Wang Y, et al. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med. 2011;3:80ps16.
15. Paladin Labs Inc. Prescribing Information: Dexedrine® (dextroamphetamine sulfate). www.paladin-labs.com/pdf-files/Dexedrine.pdf (Last accessed November 22, 2014).
16. Highlights of Prescribing Information. www.gene.com/download/pdf/xenical- prescribing.pdf (Last accessed November 22, 2014).
17. Debnath A, Parsonage D, Andrade RM, et al. A high throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med. 2012;18:956-960.
18. Dailymed. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid = 05c34ddfa0f7- 4267-83f5-d02be3defc37 combined with information from Product Monograph. Ridaura-. www.xediton.com/RIDAURA-PRODUCT%20MONOGRAPH .pdf [the PDF contains an error regarding the units of measurement, it states picograms (pg) intead of micrograms (lg)]. (Last accessed November 22, 2014).
19. ClinicalTrials.gov. Auranofin PK following oral dose administration. https://clinicaltrials.gov/ct2/show/NCT02089048 (Last accessed November 22, 2014).
20. Chaffman M, Brogden RN, Heel RC, Speight TM, Avery GS. Auranofin. Drugs 1984;27:378-424.
21. Thedu. Goldar (3 mg)-Auranofin-tablet. http://thedu.in/compare-prices/index.php/medicines-g/article/39214-goldar-3-mg-auranofin-tablet (Last accessed November 22, 2014).
22. Unitedpharmacies. Ridaura: Auranofin. www.unitedpharmacies.com/Ridaura- Auranofin.html (Last accessed November 22, 2014).
23. Business Standard. Indias median per capita income lowest among BRICS: Gallup. www.business-standard.com/article/economy-policy/india-s-medianper- capita-income-lowest-among-brics-gallup-113121600968-1.html (Last accessed November 22, 2014).